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Cancer stem cells have recently been isolated from several different solid tumors. In breast cancer, the CD44
þCD24
 /low
population is considered to comprise stem-like cells. The identiﬁcation of cancer stem cells has provided new targets for the
development of therapeutics. Oncolytic herpes simplex viruses (oHSVs) are an effective strategy for killing breast cancer cells and
treating breast tumors in preclinical models. Here, we examined the efﬁcacy of the oHSV G47D in killing breast cancer stem cells.
Human breast cancer cell line SK-BR-3 and human primary breast cancer cells were cultured in suspension under conditions
conducive to the growth of stem cells. They generated mammospheres, which had cancer stem cell properties. The proportion of
CD44
þCD24
 /low cells in these mammospheres exceeded 95%, as determined by ﬂow cytometry. The mammospheres were found
to be highly tumorigenic when implanted subcutaneously in nude BALB/c mice. G47D contains the LacZ gene, and X-gal staining of
infected cells in vitro and in vivo showed the replication and spread of the virus. G47D was found to be highly cytotoxic to the
CD44
þCD24
 /low population in vitro, even when injected at low multiplicities of infection, and G47D treatment in vivo signiﬁcantly
inhibited tumor growth compared with mock treatment. This study demonstrates that oHSV is effective against breast cancer stem
cells and could be a beneﬁcial strategy for treating breast cancer patients.
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INTRODUCTION
Breast cancer is the most common cancer among women, and
although it can be diagnosed and treated at an early stage, it is
the second leading cause of cancer-related death among women
in the United States.
1 The disease recurs, mostly metastasizes, in
about 30% of all patients with early-stage disease.
2 Conventional
chemotherapies are initially effective in disease control for
patients with metastatic disease but ultimately, most fail. Cancer
stem cells are thought to have an important role in recurrence
after treatment and contribute to the incurable nature of
metastatic breast cancer.
3 These cells have the potential for
multilineage differentiation, therapeutic resistance, hypoxic
resistance and metastasis, and have high tumorigenicity and
strong ability for cell invasion. Al-Hajj et al.
4 found that palpable
tumors were formed when a few hundred CD44
þCD24
 /low cells
were injected into the mammary fat pad of non-obese diabetic/
severe combined immunodeﬁcient mice. In this study, we found
that mammospheres are generated when the breast cancer cell
line SK-BR-3 and human primary breast cancer cells, of which a
high proportion are CD44
þCD24
 /low cells, are cultured in
suspension. An important feature of stem cell-like cells is that
unlike general tumor cells, they can initiate tumors even when a
very small number are present. The present study also found this
result. We also conﬁrmed the stem cell-like features of the
CD44
þCD24
 /low cells from among the SK-BR-3 and human
primary breast cancer cells, namely, the expression of the
common stem cell markers oct4 and sox2. To further determine
the stem cell-like characteristics of the CD44
þCD24
 /low
population, we examined them for a key marker of breast
cancer stem cells—aldehyde hydrogenase (ALDH1) activity.
5,6
Owing to their slow replication and ability to expel antitumor
drugs, these cells are believed to be responsible for the failure of
many conventional cancer therapies.
7–10
Oncolytic virotherapy is a new therapeutic strategy that is based
on the inherent cytotoxicity of viruses and their ability to replicate
and spread in tumors in a selective manner.
11 Oncolytic herpes
simplex virus (oHSV) vectors have many qualities that make them
attractive cancer therapeutic agents: They have the ability to
replicate in situ, disseminate within the tumor and transfer
therapeutic transgenes. Further, they can induce antitumor
immune responses and can be eliminated using anti-viral drugs.
They are also minimally toxic to normal tissue, a feature important
for clinical translation.
12 The second generation oHSV vector G207
is currently under clinical trials for malignant glioma.
13,14 G207
contains deletions of both copies of the g34.5 gene, which is the
major determinant of HSV neurovirulence, and has the Escherichia
coli LacZ gene in its IPC6 gene (UL39), whereby the ribonucleotide
reductase needed for replication in non-dividing cells is
inactivated.
15 In G47D, which is derived from G207, the IPC47
gene and US11 promoter are also deleted, whereby growth and
immunogenicity are enhanced and yet safety is maintained.
16
G47D has been shown to be effective in several preclinical breast
cancer models, including human xenografts, a model of metastatic
breast cancer in the brain, and spontaneously arising breast
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17–19 In the present study, we
demonstrated the efﬁcacy of G47D in suppressing cancer stem
cells in a human breast cancer stem cell model.
MATERIALS AND METHODS
Cells and viruses
Human breast cancer tissue was obtained from six breast invasive ductal
carcinoma patients who had not received chemotherapy but had
undergone modiﬁed radical mastectomy (obtained from Breast Cancer
Center of the Third Afﬁliated Hospital of Sun Yat-sen University, China). All
samples were washed with phosphate-buffered saline (PBS), treated for fat
removal, mechanically disaggregated, and then digested and ﬁltered as
described previously.
20,21 The tumor tissue was minced and digested for
about 12–18h at 371C with a solution of 100Uml
 1 collagenase I (Gibco),
150Uml
 1 hyaluronidase (Sigma), 10% calf serum (Gibco, Grand Island,
NY, USA) and 5mgl
 1 bovine insulin (Sigma, St Louis, MO, USA) in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco). The digested tissue
was strained with a 40-mm strainer, the cell suspension was washed with
PBS and the red blood cells were lysed. The cells treated by the above
steps and cells of the line SK-BR-3 (obtained from Dr Zeng Mu-sheng, Sun
Yat-sen University Cancer Center, China) were cultured in DMEM-F12
medium (Gibco) supplemented with 10mgl
 1 basic ﬁbroblast growth
factor, 20mgl
 1 epidermal growth factor (both from Peprotech, Grand
Island, NY, USA), 5mgl
 1 insulin (Gibco) and B27 (1:50; Gibco) at 371Ci n
5% CO2. Foreskin-derived ﬁbroblasts (obtained from Dr Zhang Qi,
Department of Hepatic Surgery, the Third Afﬁliated Hospital of Sun Yat-
sen University, China) that were isolated as previously described were
cultured in 1640 medium (Gibco) supplemented with 10% fetal bovine
serum (Gibco) at 371Ci n5 %C O 2.
22 G47D was constructed as described
previously.
16 The virus was grown and titered on Vero cells (African green
monkey kidney; ATCC, Manassas, VA, USA) in DMEM with glucose
(4.5gl
 1) supplemented with 10% calf serum at 371Ci n5 %C O 2.
Identiﬁcation of breast cancer stem cells
Vimentin, ﬁbronectin, cytokeratin activity was measured with immuno-
ﬂuorescent staining. Primary human breast cancer cells and foreskin-
derived ﬁbroblasts were seeded into 48-well plates at 10000 cells per well.
After overnight incubation, cells were ﬁxed in 4% paraformaldehyde for
15min at room temperature. Then cells were washed twice with PBS and
incubated with 2% BSA and 0.2% Triton X-100 in PBS for 1h at room
temperature. Next, 200ml of a primary antibody solution was added into
each well, cells were incubated overnight at 41C. Then cells were washed
twice with PBS and incubated with phycoerythrin-labeled secondary
antibody for 1h at room temperature. Finally, cells were stained with
hoechst 33342 for 10min. Immunoﬂuorescence was viewed using an
immunoﬂuorescence microscope. CD45 and CD31 activity were measured
by ﬂow cytometry with allophycocyanin-conjugated antibodies and
phycoerythrin–cyanine dye 7 (Cy7)-conjugated antibodies (both from
eBioscience, San Diego, CA, USA), respectively.
SK-BR-3 and human primary breast cancer mammosphere cells and the
adherent cells were stained with ﬂuorescein isothiocyanate -labeled anti-
CD44 and phycoerythrin-labeled anti-CD24 antibodies (both from Beck-
man Coulter (Brea, CA, USA) and sorted by ﬂow cytometry (Becton
Dickinson, Franklin Lakes, NJ, USA). The Aldeﬂuor assay was performed
according to the manufacturer’s suggested protocol (Stemcell Technologies,
Vancouver, British Columbia, Canada). Approximately 1 10
6 cells were sus-
pended in 1ml of Aldeﬂuor assay buffer containing the ALDH substrate
BODIPY aminoacetaldehyde. Immediately, 0.5ml of the mixture was trans-
ferred to another tube in the presence of the ALDH inhibitor diethylamino
benzaldehyde. The cells were incubated for 30min at 371C and assessed by
ﬂow cytometry. Immunoﬂuorescent staining of paraformaldehyde-ﬁxed
mammosphere cells of both types was performed with anti-oct4 and anti-
sox2 antibodies (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA).
ReverTra Ace-a-1 (Toyobo, Osaka, Japan) was used for semi-quantitative








In vitro cytotoxicity assessment
SK-BR-3 and human primary breast cancer mammosphere cells were
seeded in six-well plates at 1 10
5 cells per well. After 24h incubation at
371C, the cells were infected with the virus at a multiplicity of infection
(MOI) of 0.1 and 0.01, and controls cells were mock infected. The infected
cells were incubated at 371C until counting, at which point they were
washed twice with PBS, trypsinized and counted using a hemocytometer.
Animal studies
SK-BR-3 mammosphere cells (1 10
6) were implanted in the left ﬂank of 6-
week-old female BALB/c nude mice. When the formed tumors reached
approximately 5mm in maximal diameter, 50ml of the G47D virus (1 10
7
plaque-forming units (p.f.u.)) or PBS (mock) was inoculated into the tumor
(day 0), followed by repeat injections on days 3, 7 and 10. The three
longest dimensions were measured twice a week using an external caliper,
and the tumor volume was calculated (length width height).




5 SK-BR-3 mammosphere cells were implanted in the left ﬂank
of 6-week-old female BALB/c nude mice.
All animal procedures were approved by the Animal Care and Use
Committee of Sun Yat-sen University.
Tumor tissue analysis by ﬂow cytometry
Tumor tissue was minced and digested for about 12–18h at 371C in DMEM
containing 100Uml
 1 collagenase I, 150Uml
 1 hyaluronidase, 10% calf
serum and 5mgl
 1 bovine insulin. The digested tissue was strained with a
40-mm strainer, the cell suspension was washed with PBS, the red blood
cells were lysed, and then the proportion of CD44
þCD24
 /low was
measured by ﬂow cytometry.
Histological analysis
Tumor tissue was harvested and frozen at  801C. Cryostat sections of 5mm
thickness were then prepared and stained with an In Situ b-galactosidase
Staining Kit (Beyotime Institute of Biotechnology, Shanghai, China).
Statistical analysis
Data are presented as the mean±standard deviation (s.d.). Independent
samples t-test and w
2 test were used to analyze the signiﬁcance of differences
between the two groups. SPSS version 13.0 software (SPSS Inc., Chicago, IL,
USA) was used, and a P-value of less than 0.05 was considered signiﬁcant.
RESULTS
Identiﬁcation of human primary breast cancer cells
The purity of the primary mammospheres was veriﬁed by using
ﬂow cytometry and immunostaining. We found that no more than
0.5% of the primary mammospheres were positive for CD31 or
CD45 by ﬂow cytometry (Figures 1a and b). These primary
mammospheres were negative for ﬁbroblastic markers such as
vimentin and ﬁbronectin, whereas these cells strongly expressed
cytokeratin (Figures 1c and d).
24,25 Taken together, these
observations clarify that these primary mammospheres were
prepared with minimal contamination by ﬁbroblast populations,
hematopoietic cells or endothelial cell.
Identiﬁcation of breast cancer stem cells
Currently, mammosphere cultures and ﬂow cytometric sorting for
the CD44
þCD24
 /low subpopulation are the main methods for
enrichment of breast cancer stem/progenitor cells.
4,26–28 We used
suspension culture of SK-BR-3 and human primary breast cancer
cells to generate mammospheres (Figure 2b) in which the CD44
þ
CD24
 /low subpopulation was enriched to 99.6±0.07% and
95.3±1.2%, respectively (Figure 2a). The mammosphere cells
were then allowed to form adherent cultures, thereby enabling
the easy detection of oHSV G47D cytotoxicity. The adherent
cultures (Figure 2d) of SK-BR-3 and human primary breast cancer
cells retained a high proportion of CD44
þCD24
 /low cells
(96.7±1.7%, 92.1±2.5%, respectively; Figure 2c). The difference
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þCD24
 /low cells between the
suspended and adherent mammospheres was not found to be
statistically signiﬁcant (P40.05). Further, under normal conditions,
the proportion of mammospheres formed by the SK-BR-3 cells
(4.1±0.3%) was signiﬁcantly higher than that formed by the
human primary breast cancer cells (2.7±1.1%) (Po0.05).
To further evaluate the stem cell characteristics of the CD44
þ
CD24
 /low population, the expression of Oct4 and Sox2 was
examined. The SK-BR-3 and human primary breast cancer cell
mammospheres expressed Oct4 and Sox2 protein, as detected by
immunoﬂuorescent analysis (Figures 3a and b), and Oct4 and Sox2
mRNA was detected by RT-PCR (Figure 3c).
Flow cytometry and the ALDEFLUOR assay for detecting
ALDH activity showed the percentage of ALDEFLUOR-positive
SK-BR-3 and human primary breast cancer mammospheres
to be 37.6±1.5% and 27.3±1.3% respectively. These values
were over 10-fold higher than those of the SK-BR-3 and
human primary breast cancer cells, which were 2.9±0.5% and
1.5±0.3% respectively (Po0.001; Figure 4). To observe the tumor
formation rate of possible stem cells, 1 10
3,1 10
4 and 1 10
5
SK-BR-3 mammosphere cells and parental cells were implanted in
the left ﬂank of 6-week-old female nude BALB/c mice. All
mice developed tumors when injected with 1 10
4 or 1 10
5
SK-BR-3 mammosphere cells. However, one of the mice developed
tumors when injected with 1 10
5 SK-BR-3 parental cells. This
difference was statistically signiﬁcant and strongly supports the
conclusion that the tumor formation rate of mammosphere cells is
much higher than that of non-mammosphere cells (Table 1).
In vitro cytotoxicity
G47D was found to be highly cytotoxic to both types of
mammosphere cells in vitro. Over 50% of the cells were killed
by days 3 and 4 when infected with the virus at an MOI of 0.1 and
0.01, respectively (Figure 5, left); similarly, over 90% of the non-
mammosphere cells were killed by day 4 when infected with the
virus at an MOI of 0.1 and 0.01 (Figure 5, right). The spread of the
G47D vector in adherent cultures was visualized by X-gal
histochemical analysis of the infected cells (Figure 6). Most cells
were dead by day 6, because of which the number of X-gal-
positive cells detected decreased.
Treatment of tumors in vivo
CD44
þCD24
 /low cells from the mammospheres formed tumors
when injected into the left ﬂank of 6-week-old female nude BALB/c
Figure 1. Identiﬁcation of human primary breast cancer cells. Flow cytometric analysis for endothelial marker CD31 (a) and hematopoietic
marker CD45 (b) on human breast cancer cells. The percentage of CD31- or CD45-positive cells is indicated. Immunoﬂuorescent staining of
vimentin, ﬁbronectin and cytokeratin in primary cancer cells (c) and foreskin-derived ﬁbroblasts (d). Fibroblasts served as a positive control for
vimentin and ﬁbronectin. We found that foreskin-derived ﬁbroblasts strongly expressed ﬁbroblastic markers vimentin and ﬁbronectin, but
these cells were negative for cytokeratin. In contrast, human primary breast cancer cells strongly expressed cytokeratin, whereas these cells
were negative for vimentin or ﬁbronectin. Scale bar, 50mm.
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not form tumors (n¼10; followed up until day 58). To evaluate the
antitumor efﬁcacy of G47D, the established tumors (approximately
5mm in maximal diameter) were inoculated with the virus (1 
10
7p.f.u.) or PBS (mock) on days 0, 3, 7 and 10. G47D treatment
signiﬁcantly inhibited tumor growth, (Po0.05; Figures 7a and c). No
mice had apparent tumors on days 21 and 24 after injection with
G47D. In a separate experiment, mice were killed and X-gal
histochemical analysis was performed to detect infected cells
indicative of G47D replication. Replication was observed even 13
days after a single virus injection (Figure 7b). When tumors were
removed from mice 58 days after implantation, the proportion of
Figure 2. Mammosphere cells were analyzed by ﬂow cytometry. (a) The proportion of CD44
þCD24
 /low cells among the SK-BR-3
mammosphere cells in suspension culture was 99.6±0.07%. (b) Microscopic image of mammosphere in suspension culture. (c) The
proportion of CD44
þCD24
 /low cells among the SK-BR-3 mammosphere cells in adherent culture was 96.7±1.7%. (d) Microscopic image of
mammosphere in adherent culture.
Figure 3. Stem cell features of mammosphere cells. Immunoﬂuorescent staining of Oct4 (a) and Sox2 (b) in SK-BR-3 mammosphere cells. Oct4
and Sox2 mRNA was detected by RT-PCR (c). Lanes 1–4 show mammospheres of primary breast cancer cells from different tumors, lane 5
shows non-mammosphere cells, lane 6 show mammosphere cells of SK-BR-3, M is the molecular size ladder. b-Actin served as a control for
total RNA.
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 /low cells was reduced to between 3% and 5% in the
mock- and oHSV-treated groups, respectively (Figure 8), similar to
the level seen initially in non-treated SK-BR-3 cells (data not shown).
DISCUSSION
Cancer stem cells have been proposed as initiators of cancer and
may be responsible for cancer recurrence, development of
metastases and resistance to therapy.
3,28,29 Breast cancer stem
cells have been isolated using various techniques, including sorting
for cell surface markers, serum-free suspension culture, sorting for
side population cells and sorting for ALDH.
6,21,26,29–31 We used
serum-free suspension culture to enrich stem cells, which we then
detected as the CD44
þCD24
 /low population and ALDH activity by
ﬂow cytometry. The percentage of ALDEFLUOR-positive SK-BR-3 and
human primary breast cancer mammospheres are 37.6±1.5% and
27.3±1.3%, respectively, which is signiﬁcantly higher than those of
the SK-BR-3 and human primary breast cancer cells, (Po0.001) and
the proportion of CD44
þCD24
 /low cells in the non-mammosphere
cells and mammosphere cells was about 4% and 99%, respectively.
The purity of the primary mammospheres is also an important
factor, which was veriﬁed with minimal contamination by ﬁbroblast
populations, hematopoietic cells or endothelial cell by using ﬂow
cytometry and immunostaining. The tumor formation rate after
implantation of 1 10
3 mammosphere cells in 6-week-old female
nude BALB/c mice was up to 50%. Although all the mice developed
tumors when injected with 1 10
4 or 1 10
5 SK-BR-3
mammosphere cells, only one of the six mice developed tumors
when injected 1 10
5 non-mammosphere cells. Thus, it is clear that
mammosphere cells were almost 100-fold more tumorigenic than
non-mammosphere cells, indicating that our serum-free suspension
culture enriched cancer stem cells. Similar results for SK-BR-3 cells
have been reported previously.
32
In this study, we found that suspended mammosphere cells
tended toward adherent growth in the course of passage, though
the reason for this phenomenon is not very clear at present.
However, the in vitro cytotoxicity test is easy to conduct because
of the phenomenon of adherent mammosphere growth. When
mammospheres were cultured in the serum medium, the
frequency at which the characteristics of stem cells was observed
Figure 4. ALDEFLUOR-positive cell population of SK-BR-3 mammosphere cells and parental cells. The percentage of ALDEFLUOR-positive SK-
BR-3 mammosphere cells was 37.6±1.5%, whereas the percentage of ALDEFLUOR-positive SK-BR-3 parental cells was 2.9±0.5% (Po0.001,
independent samples t-test).
Table 1. The tumor formation rate of SK-BR-3 mammosphere cells
and SK-BR-3 cells in BALB/c mice





SK-BR-3 mammosphere cells 2/4 6/6* 6/6*
SK-BR-3 cells 0/4 0/6 1/6
*Po0.05, w
2 test.
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changes with differentiation. The mammospheres also expressed
the stem cell markers Oct4 and Sox2, which supported their stem-
like phenotype.
Oncolytic virotherapy has been translated to the clinic, with
numerous oncolytic viruses being tested in patients with different
cancers.
33 This includes studies on oHSV in patients with
subcutaneous nodules of recurrent breast cancer.
34,35 Although
the breast cancer stem cells were susceptible to G47D,i tt o o ka b o u t
6 days to reduce viability by over 90% when the virus was injected
at an MOI of 0.01. Over 90% of the non-stem cells were killed by
day 4 when injected at an MOI of 0.1 or 0.01. Thus, the cytotoxicity
of G47D to CD44
þCD24
 /low cells was weaker than that to breast
cancer cells cultured under standard conditions. Infection of
mammospheres with G47D at a low MOI blocked their ability to
form tumors in vivo. When the tumors were removed from the mice
58 days after implantation, the proportion of CD44
þCD24
 /low was
reduced almost 20-fold, indicating that cancer stem cells differen-
tiate during tumor growth, as has been reported previously.
4
Therefore, the bulk of tumor cells are not stem cell-like, and these
Figure 5. In vitro killing of mammosphere cells and parental cells of SK-BR-3 by G47D. Adherent cultured mammosphere cells and parental
cells of SK-BR-3 in six-well dishes were infected with G47D at an MOI of 0.01 or 0.1 or with PBS (mock), and the average number of cells from
duplicate wells is plotted as the percent in the mock wells.
Figure 6. X-gal staining of human primary breast cancer mammospheres infected with G47D. Adherent human primary breast cancer
mammospheres cultures in six-well dishes were infected with G47D at an MOI of 0.01 or 0.1 or with PBS (mock), and the cells were stained
with X-gal to identify infected cells (blue).
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G47D inhibited the growth of established tumors.
To our knowledge, this is the ﬁrst report of the treatment of
breast cancer stem cells with oHSV. The oHSV vector G47D was
effective in killing human breast cancer stem cells in vitro and
treating tumors in an animal model. The ability of oHSV to target
breast cancer stem cells efﬁciently is an important attribute that
supports the possibility of successful clinical translation.
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